NEJM November 14, 2019
What do health care leaders and providers think about drug prices? A recent survey of NEJM Catalyst Insights Council members — composed of clinicians, clinical leaders, and executives at organizations directly involved in health care delivery — shows strong opinions about the impact of high prices, who’s to blame, and how to fix the problem.
Nearly two-thirds (62%) of Insights Council members believe drug prices are a major contributor to the cost of health care, and another third (35%) consider drug prices to be a moderate contributor to overall health care costs. The survey was conducted in September 2019.
The 606 survey respondents put the onus for high pricing on biopharmaceutical companies first, with 92% saying these companies are extremely...
Today's Sponsors
Today's Sponsor